Development of Angiogenic Cell and Gene Therapy by Transplantation of Umbilical Cord Blood with Vascular Endothelial Growth Factor Gene

• IKEDA Yukihiro

  Second Department of Internal Medicine, Nihon University School of Medicine

• FUKUDA Noboru

  Second Department of Internal Medicine, Nihon University School of Medicine Department of Advanced Medicine, Division of Cell Regeneration and Transplantation, Nihon University School of Medicine

• WADA Mika

  Department of Advanced Medicine, Division of Cell Regeneration and Transplantation, Nihon University School of Medicine

• MATSUMOTO Taro

  Second Department of Internal Medicine, Nihon University School of Medicine Department of Advanced Medicine, Division of Cell Regeneration and Transplantation, Nihon University School of Medicine

• SATOMI Aya

  Department of Advanced Medicine, Division of Cell Regeneration and Transplantation, Nihon University School of Medicine

• YOKOYAMA Shin-Ichiro

  Second Department of Internal Medicine, Nihon University School of Medicine

• SAITO Satoshi

  Second Department of Internal Medicine, Nihon University School of Medicine

• MATSUMOTO Koichi

  Second Department of Internal Medicine, Nihon University School of Medicine

• KANMATSUSE Katsuo

  Second Department of Internal Medicine, Nihon University School of Medicine

• MUGISHIMA Hideo

  Department of Advanced Medicine, Division of Cell Regeneration and Transplantation, Nihon University School of Medicine

書誌事項

タイトル別名

• <B>Development of Angiogenic Cell and Gene Therapy by Transplantation of Umbilical Cord Blood with Vascular Endothelial Growth Factor Gene</B>

抄録

Endothelial progenitor cells (EPCs) are present in the mononuclear cells (MNCs) of umbilical cord blood and peripheral blood. To establish the efficiency of angiogenic cell and gene therapies, we transfected the human vascular endothelial growth factor (hVEGF) gene into cord blood MNCs to enhance endothelialization. MNCs from cord blood and peripheral blood were isolated and transfected with pCR3 expressing hVEGF165 or GFP by the Hemagglutinating Virus of Japan (HVJ)-envelope and the cells were cultured in endothelium basal medium-2. The number of attached cells from cord blood was higher than that from peripheral blood. Attached cells expressed Flk-1, VE-cadherin, PECAM-1, CD34, and Tie-2. The increase in the number of attached cells was transient with the transfection of vascular endothelial growth factor (VEGF) gene early in the experimental period. Flt-1 mRNA was not expressed early in the culture period, but was expressed at 2 weeks after separation. VEGF gene transfer into MNCs at 12 days after separation, i.e., when Flt-1 mRNA was expressed continuously, increased the number of attached cells. We evaluated the effects of the transplantation of cord blood MNCs expressing the hVEGF gene on regional blood flow in an ischemic area in a rat model of chronic hindlimb ischemia. Blood flow was significantly improved in nude rats that received transplanted control MNCs. Transplantation of cord blood MNCs transfected with the hVEGF gene yielded greater improvements in blood flow. These results indicate that the hVEGF gene enhances endothelialization of EPCs, and that the transplantation of cord blood MNCs transfected with the VEGF gene may be feasible for the treatment of ischemic diseases as a type of angiogenic cell and gene therapy. (Hypertens Res 2004; 27: 119-128)

収録刊行物

• Hypertension Research

  Hypertension Research 27 (2), 119-128, 2004

  日本高血圧学会

キーワード

• <B>cord blood</B>
• <B>gene and cell therapy</B>
• <B>vascular endothelial growth factor</B>
• <B>angiogenesis</B>
• <B>regenerative medicine</B>

詳細情報

• CRID: 1390282679696964736
• NII論文ID: 10012843652
• NII書誌ID: AA10847079
• DOI: 10.1291/hypres.27.119
• COI: 1:CAS:528:DC%2BD2cXjs12qtrY%3D
• ISSN: 13484214
• ISSN: 09169636
• PubMed: 15005275
• Web Site: https://search.jamas.or.jp/link/ui/2004171486
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可